Ergomed PLC
LSE:ERGO

Watchlist Manager
Ergomed PLC Logo
Ergomed PLC
LSE:ERGO
Watchlist
Price: 1 346 GBX Market Closed
Market Cap: 701.1m GBX
Have any thoughts about
Ergomed PLC?
Write Note

Intrinsic Value

The intrinsic value of one ERGO stock under the Base Case scenario is 1 137.89 GBX. Compared to the current market price of 1 346 GBX, Ergomed PLC is Overvalued by 15%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ERGO Intrinsic Value
1 137.89 GBX
Overvaluation 15%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Ergomed PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ERGO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ERGO?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Life Sciences Tools & Services Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Ergomed PLC

Provide an overview of the primary business activities
of Ergomed PLC.

What unique competitive advantages
does Ergomed PLC hold over its rivals?

What risks and challenges
does Ergomed PLC face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Ergomed PLC.

Provide P/S
for Ergomed PLC.

Provide P/E
for Ergomed PLC.

Provide P/OCF
for Ergomed PLC.

Provide P/FCFE
for Ergomed PLC.

Provide P/B
for Ergomed PLC.

Provide EV/S
for Ergomed PLC.

Provide EV/GP
for Ergomed PLC.

Provide EV/EBITDA
for Ergomed PLC.

Provide EV/EBIT
for Ergomed PLC.

Provide EV/OCF
for Ergomed PLC.

Provide EV/FCFF
for Ergomed PLC.

Provide EV/IC
for Ergomed PLC.

Show me price targets
for Ergomed PLC made by professional analysts.

What are the Revenue projections
for Ergomed PLC?

How accurate were the past Revenue estimates
for Ergomed PLC?

What are the Net Income projections
for Ergomed PLC?

How accurate were the past Net Income estimates
for Ergomed PLC?

What are the EPS projections
for Ergomed PLC?

How accurate were the past EPS estimates
for Ergomed PLC?

What are the EBIT projections
for Ergomed PLC?

How accurate were the past EBIT estimates
for Ergomed PLC?

Compare the revenue forecasts
for Ergomed PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Ergomed PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Ergomed PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Ergomed PLC compared to its peers.

Compare the P/E ratios
of Ergomed PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Ergomed PLC with its peers.

Analyze the financial leverage
of Ergomed PLC compared to its main competitors.

Show all profitability ratios
for Ergomed PLC.

Provide ROE
for Ergomed PLC.

Provide ROA
for Ergomed PLC.

Provide ROIC
for Ergomed PLC.

Provide ROCE
for Ergomed PLC.

Provide Gross Margin
for Ergomed PLC.

Provide Operating Margin
for Ergomed PLC.

Provide Net Margin
for Ergomed PLC.

Provide FCF Margin
for Ergomed PLC.

Show all solvency ratios
for Ergomed PLC.

Provide D/E Ratio
for Ergomed PLC.

Provide D/A Ratio
for Ergomed PLC.

Provide Interest Coverage Ratio
for Ergomed PLC.

Provide Altman Z-Score Ratio
for Ergomed PLC.

Provide Quick Ratio
for Ergomed PLC.

Provide Current Ratio
for Ergomed PLC.

Provide Cash Ratio
for Ergomed PLC.

What is the historical Revenue growth
over the last 5 years for Ergomed PLC?

What is the historical Net Income growth
over the last 5 years for Ergomed PLC?

What is the current Free Cash Flow
of Ergomed PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for Ergomed PLC.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Ergomed PLC

Current Assets 66.9m
Cash & Short-Term Investments 26m
Receivables 38.3m
Other Current Assets 2.6m
Non-Current Assets 66.5m
PP&E 5.2m
Intangibles 55.9m
Other Non-Current Assets 5.5m
Current Liabilities 37.3m
Accounts Payable 4.3m
Accrued Liabilities 9.5m
Other Current Liabilities 23.5m
Non-Current Liabilities 5.2m
Long-Term Debt 1.4m
Other Non-Current Liabilities 3.8m
Efficiency

Earnings Waterfall
Ergomed PLC

Revenue
152.1m GBP
Cost of Revenue
-90.2m GBP
Gross Profit
61.9m GBP
Operating Expenses
-41.1m GBP
Operating Income
20.7m GBP
Other Expenses
-5.7m GBP
Net Income
15m GBP

Free Cash Flow Analysis
Ergomed PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ERGO Profitability Score
Profitability Due Diligence

Ergomed PLC's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Exceptional 3-Years Revenue Growth
Positive 3-Year Average ROIC
62/100
Profitability
Score

Ergomed PLC's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

ERGO Solvency Score
Solvency Due Diligence

Ergomed PLC's solvency score is 92/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Negative Net Debt
Low D/E
92/100
Solvency
Score

Ergomed PLC's solvency score is 92/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ERGO Price Targets Summary
Ergomed PLC

There are no price targets for ERGO.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ERGO?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for ERGO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Ergomed PLC Logo
Ergomed PLC

Country

United Kingdom

Industry

Life Sciences Tools & Services

Market Cap

683.5m GBP

Dividend Yield

0%

Description

Ergomed Plc is a clinical stage development company, which provides specialist services to the pharmaceutical and biotechnology industries spanning all phases of clinical development, post-approval pharmacovigilance, and medical information. The company is headquartered in Guildford, Surrey. The company went IPO on 2014-07-15. The firm operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV). CRO segment is the process of developing medical therapies, drugs and knowledge for safe use in healthcare. PV segment is engaged in the activities relating to the detection, understanding and prevention of adverse effects or other drug-related problems throughout its lifecycle. The firm operates approximately 24 offices around the world, providing its services in over 100 countries globally. The company operates in North America, United Kingdom and Europe, Middle East and Africa, and Asia. The Company’s subsidiaries include Ergomed GmbH, Ergomed Sp. z o.o, Ergomed d.o.o. Beograd, Ergomed Clinical Research Inc., MS Clinical Services, LLC and MedSource UK Ltd.

Contact

SURREY
Guildford
1 Occam Court, Occam Road
+441483503205.0
www.ergomedplc.com

IPO

2014-07-15

Employees

1 009

Officers

Founder & Exec. Chairman
Dr. Miroslav Reljanovic
CFO & Exec. Director
Mr. Richard T. Barfield
Chief Transformation & Technology Officer
Mr. Michael William Spiteri
Chief Information Officer
Mr. Shaun Hopgood
Head of Risk Management & Pharmacoepidemiology
Dr. Michael Forstner
Pres of PrimeVigilance
Ms. Sally Amanuel
Show More
Pres of Clinical Research
Dr. Gordana Tonkovic
Sr. VP of Global Devel.
Ms. Ronel Steyn
Sr. Vice-Pres of Capital Markets & Strategy
Keith Byrne
Deputy CFO
Jonathan Curtain
Show Less

See Also

Discover More
What is the Intrinsic Value of one ERGO stock?

The intrinsic value of one ERGO stock under the Base Case scenario is 1 137.89 GBX.

Is ERGO stock undervalued or overvalued?

Compared to the current market price of 1 346 GBX, Ergomed PLC is Overvalued by 15%.

Back to Top